Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. The Lancet 390 , 849-860 (2017). Nyberg WA, et al.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. By correcting these mutations, gene-modifying and editing therapies hold the promise of long-term, potentially curative treatments.

Therapies 98

Therapies Disease RNA Engineering 98

The Pharma Data

DECEMBER 17, 2020

San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour. in North America) in late 2017.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

Drug Target Review

NOVEMBER 7, 2024

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52

Disease Immune Response Regulations Engineering 52

PerkinElmer

AUGUST 25, 2019

With no natural enemies left to stop tumor cells, they proliferate and lead to tumors that can even adapt to various treatments to evade immunity. Reference: Jeanine Hinterneder, “Measuring PD-L1 Expression in Breast Cancer Cell Lines With Alpha LISA,” PerkinElmer Application Note, 2017, September 3, 2017.

Protein Expression 52

Protein Expression Immune Response Treatment Research 52

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Prior to the founding of IN8bio, from 2014 to 2017, Mr Ho was the Founder and Managing Partner at AlephPoint Capital, a private healthcare investment fund. gammadelta T cells link innate and adaptive immune responses.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Target Review

MARCH 21, 2024

Could you elaborate on the safety profile observed in the study regarding the administration and treatment with Bobcat mRNA-DMD and how it compares to current therapeutic approaches for Duchenne muscular dystrophy? AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. 2014 Jan 1;3.

Therapies 64

Therapies RNA Immune Response Treatment 64

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan. +44 (0)20 7495 2379.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

SEPTEMBER 10, 2021

POSEIDON Phase III trial showed the addition of a short course of tremelimumab to Imfinzi plus chemotherapy improved patient outcomes without an increase in treatment discontinuation. The results of POSEIDON confirm that tremelimumab added to Imfinzi and chemotherapy is an effective, well-tolerated treatment in this setting.”.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

OCTOBER 28, 2020

We are pursuing an accelerated approval pathway for remestemcel-L in the treatment of children with SR-aGVHD, and a parallel approval pathway for COVID-19 ARDS if the randomized controlled Phase 3 trial is positive.”. agents and even among responders, up to 10% will lose their response to the drug every year.

Treatment 40

Treatment Trials Disease Production 40

The Pharma Data

DECEMBER 15, 2020

The human monoclonal antibody targets specific immune plasma cells. Treatment induced sustainable clinical responses and reduced systemic inflammation. Daratumumab already is approved for the treatment of multiple myeloma. The researchers regulated the abnormal immunological memory processes found in these patients.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

NOVEMBER 10, 2020

We believe the scientific rationale for oral treatment with Foralumab is logical to facilitate topical action at the inflamed sites in the gastrointestinal tract. 2017) Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Dev Immunol 2012, 425021.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

APRIL 7, 2023

1 Over two thirds of patients are diagnosed with advanced disease which can progress quickly, often within two years, diminishing their quality of life despite treatment. DUO-O enrolled over 1200 patients across all treatment arms at 179 study locations. Ovarian cancer is one of the most common gynaecologic cancers.

Trials 40

Trials DNA Treatment Therapies 40

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. 12)AZD7442 is being studied in a comprehensive clinical trial programme for both prevention and treatment of COVID-19 in over 9,000 participants. 2017; 61(3): e01714-16.

Trials 52

Trials Vaccine Virus Pharmacokinetics 52

The Pharma Data

JULY 23, 2021

Opdivo was first granted this indication in 2017 under the FDA’s accelerated approval program, making it the first immunotherapy agent to be approved for use in this setting. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. “We

Treatment 52

Treatment Trials Therapies Disease 52

The Pharma Data

MARCH 11, 2021

In HCC, despite evolution of the treatment landscape over the past few years, we believe Opdivo continues to address an unmet medical need for patients in the post-sorafenib setting, and we appreciate the opportunity to discuss this in more depth with the Committee.”. Waxman, M.D., INDICATIONS.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

NOVEMBER 1, 2020

A patent application was filed in July 202 0 to protect the potential use of nasally administered Foralumab for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Dr Howard Weiner, who is the Robert L. Forward-Looking Statements.

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

SEPTEMBER 15, 2020

Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation. The prophylactic steroid treatment was also changed from 1 mg/kg to an intermediate dose of 2mg/kg.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

JUNE 18, 2021

The FDA previously granted Fast Track designation for PREVNAR 20 in September 2017 for use in adults aged 18 years or older. pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved based on immune responses. Adults with weakened immune systems (eg, HIV infection, leukemia) may have a reduced immune response.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

Broad Institute

OCTOBER 15, 2024

He investigated using probiotic bacteria as a possible treatment for C. After completing his PhD in 2017, Brown joined Xavier’s lab as a postdoctoral researcher and has been at the Broad ever since, now as a staff scientist. difficile colitis, a severe bacterial infection in the colon that frequently resists antibiotics.

Disease 125

Disease Immune Response Research Science 125

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. 2017; 377 (10): 936-946. 2019 May 23;380(21):2082].

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

MARCH 16, 2021

Durability: 1,2 Robust joint and skin response rates and mean improvements from baseline in outcome measures were maintained through two years, and approximately 90 percent of patients randomized to TREMFYA q4w or q8w continued treatment with TREMFYA through Week 100. TREMFYA was approved in the U.S. TREMFYA was approved in the U.S.

Treatment 52

Treatment Disease Pharmacokinetics Therapies 52

The Pharma Data

OCTOBER 26, 2020

The treatment induced HPV-specific T-cell responses and was associated with increased levels of immune cell infiltration in the tumors and expression of genes associated with activation of the immune system. An overall response rate of 23.5% and a median PFS of 5.6

Vaccine 40

Vaccine Trials Treatment Virus 40

The Pharma Data

DECEMBER 21, 2020

“The recent results from our NAVIGATOR trial were impressive, both in terms of the overall clinical data and the reduction in exacerbation rate with tezepelumab treatment, and we continue to work with AstraZeneca on planned regulatory filings in 2021. Detailed results from the SOURCE trial will be presented at a future medical meeting.

Trials 40

Trials Production Clinical Trials Therapies 40

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. In addition, treatments and supportive care approaches used for other forms of myocarditis, such as viral myocarditis, don’t work for this type. “We

Immune Response 125

Immune Response Medical Schools Clinical Trials Treatment 125

Broad Institute

NOVEMBER 6, 2024

These patients had been given the revolutionary immunotherapy drugs known as immune checkpoint inhibitors (ICIs), which take the brakes off the body’s immune system so that it can fight cancer. With immunotherapy, it awakens your immune system in a way that’s like a fire in a bush — it doesn’t stop.

Research 131

Research Immune Response Hospitals Therapies 131